# Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

> **NCT00088049** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 560 (—)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** Aripiprazole

## Key facts

- **NCT ID:** NCT00088049
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 560 (—)
- **Last updated:** 2007-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088049, "Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00088049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*